Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study

Pavone, C.; Pavone-Macaluso, M.

Risultato della ricerca: Article

6 Citazioni (Scopus)

Abstract

Clinical use of recombinant tumor necrosis factor-alpha is strongly limited by its severe toxicity, mainly cardiovascular, when systemically administered. Recent studies suggest that topical (intrapleural, intraperitoneal, intratumoral) administration is free of significant toxicity. Human recombinant tumor necrosis factor-alpha was administered intravesically, at a dose of 500 mg dissolved in 30 ml of phosphate buffer (pH 7.6-7.8) plus 0.25% human albumin, weekly for two months to 18 patients with papillary transitional cell carcinoma of the bladder. Of the 15 evaluable patients, four (26%) achieved a complete response. Systemic and local tolerability were excellent.
Lingua originaleEnglish
pagine (da-a)100-103
Numero di pagine4
RivistaInternational Journal of Urology
Volume2
Stato di pubblicazionePublished - 1995

Cita questo

Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study. / Pavone, C.; Pavone-Macaluso, M.

In: International Journal of Urology, Vol. 2, 1995, pag. 100-103.

Risultato della ricerca: Article

Pavone, C.; Pavone-Macaluso, M. 1995, 'Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study', International Journal of Urology, vol. 2, pagg. 100-103.
Pavone, C.; Pavone-Macaluso, M. Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study. International Journal of Urology. 1995;2:100-103.
Pavone, C.; Pavone-Macaluso, M. / Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study. In: International Journal of Urology. 1995 ; Vol. 2. pagg. 100-103.
@article{0d96feb823344f4aa29b9f05199a3f9e,
title = "Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study",
abstract = "Clinical use of recombinant tumor necrosis factor-alpha is strongly limited by its severe toxicity, mainly cardiovascular, when systemically administered. Recent studies suggest that topical (intrapleural, intraperitoneal, intratumoral) administration is free of significant toxicity. Human recombinant tumor necrosis factor-alpha was administered intravesically, at a dose of 500 mg dissolved in 30 ml of phosphate buffer (pH 7.6-7.8) plus 0.25{\%} human albumin, weekly for two months to 18 patients with papillary transitional cell carcinoma of the bladder. Of the 15 evaluable patients, four (26{\%}) achieved a complete response. Systemic and local tolerability were excellent.",
author = "{Pavone, C.; Pavone-Macaluso, M.} and Vincenzo Serretta and Bruna Piazza",
year = "1995",
language = "English",
volume = "2",
pages = "100--103",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study

AU - Pavone, C.; Pavone-Macaluso, M.

AU - Serretta, Vincenzo

AU - Piazza, Bruna

PY - 1995

Y1 - 1995

N2 - Clinical use of recombinant tumor necrosis factor-alpha is strongly limited by its severe toxicity, mainly cardiovascular, when systemically administered. Recent studies suggest that topical (intrapleural, intraperitoneal, intratumoral) administration is free of significant toxicity. Human recombinant tumor necrosis factor-alpha was administered intravesically, at a dose of 500 mg dissolved in 30 ml of phosphate buffer (pH 7.6-7.8) plus 0.25% human albumin, weekly for two months to 18 patients with papillary transitional cell carcinoma of the bladder. Of the 15 evaluable patients, four (26%) achieved a complete response. Systemic and local tolerability were excellent.

AB - Clinical use of recombinant tumor necrosis factor-alpha is strongly limited by its severe toxicity, mainly cardiovascular, when systemically administered. Recent studies suggest that topical (intrapleural, intraperitoneal, intratumoral) administration is free of significant toxicity. Human recombinant tumor necrosis factor-alpha was administered intravesically, at a dose of 500 mg dissolved in 30 ml of phosphate buffer (pH 7.6-7.8) plus 0.25% human albumin, weekly for two months to 18 patients with papillary transitional cell carcinoma of the bladder. Of the 15 evaluable patients, four (26%) achieved a complete response. Systemic and local tolerability were excellent.

UR - http://hdl.handle.net/10447/356860

M3 - Article

VL - 2

SP - 100

EP - 103

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

ER -

Accesso al documento